Share This Page
Drugs in ATC Class D10AF
✉ Email this page to a colleague
Drugs in ATC Class: D10AF - Antiinfectives for treatment of acne
Showing 1 to 4 of 4 entries
D10AF Market Analysis and Financial Projection
The ATC Class D10AF (Antiinfectives for treatment of acne) encompasses topical and systemic antimicrobial agents primarily used to treat acne, with a focus on antibiotics like clindamycin and nadifloxacin. Below is an analysis of its market dynamics and patent landscape:
Market Dynamics
Growth Drivers
- Rising Acne Prevalence: Over 50 million Americans suffer from acne annually, with similar trends globally[12][16]. Hormonal changes, pollution, and lifestyle factors contribute to rising cases, especially among adolescents and adults[7][16].
- Demand for Topical Treatments: Topical antibiotics (e.g., clindamycin) dominate due to ease of use and efficacy. The topical segment held 47.5% of the global acne drugs market in 2023[10].
- Innovative Formulations: Combination therapies (e.g., clindamycin + benzoyl peroxide) and novel solutions like Dermata’s XYNGARI™ (a weekly topical treatment)[9] enhance patient compliance and outcomes.
- OTC Availability and Online Sales: Retail and online pharmacies drive accessibility, with platforms like Amazon and Walmart offering discounted acne medications[7][12].
Market Projections
| Market Segment | 2023/2024 Value | 2030/2034 Projection | CAGR |
|---|---|---|---|
| Global Acne Drugs | $11.17B (2024) | $19.95B (2034) | 6%[7] |
| U.S. Acne Treatment | $5.28B (2023) | $7.27B (2030) | 4.7%[12] |
| Anti-Acne Drugs | $5B (2023) | $8.04B (2031) | 6%[14] |
Patent Landscape
Key Trends
-
Novel Therapies:
- Fermentation-Derived Antimicrobials: Patents like US20170224743A1 leverage Leuconostoc bacterium fermentation products to create non-antibiotic treatments[13].
- Spongilla Technology: Dermata’s XYNGARI™ (patented in 2025) uses freshwater sponges for targeted acne treatment with minimal side effects[9].
-
Combination Therapies:
- Antibiotic + Retinoid: Clindamycin paired with adapalene or tretinoin improves efficacy[8][10].
- Triple-Action Formulations: Bausch Health’s Cabtreo (clindamycin + benzoyl peroxide + adapalene) received FDA approval in 2023[10].
-
Expiring Patents and Generics:
- Clindamycin’s patent expiration has spurred generic production (e.g., Aurobindo Pharma)[4], reducing costs but increasing competition.
Strategic Moves
- R&D Investments: Companies like Galderma and Johnson & Johnson focus on AI-driven ATC systems and biologics to address antibiotic resistance[5][16].
- Geographic Expansion: Sun Pharma and Cassiopea collaborate to distribute acne treatments in Asia-Pacific[16].
Competitive Landscape
| Company | Key Developments |
|---|---|
| Dermata Therapeutics | Launched XYNGARI™ (Phase 3 trial results expected 2025)[9]. |
| Bausch Health | Released ARAZLO (Canada, 2022) and IDP-126 Gel (Phase 3 success, 2021)[16]. |
| Galderma | Markets Differin (adapalene) and invests in AI for personalized treatments[10]. |
Challenges and Opportunities
- Antibiotic Resistance: Prolonged use of topical antibiotics necessitates alternative therapies[10][13].
- Regulatory Hurdles: Stricter FDA guidelines for systemic antibiotics push demand for safer topicals[12].
- Emerging Markets: Asia-Pacific shows high growth potential due to rising disposable incomes and skincare awareness[14][16].
Key Takeaways
- The D10AF market thrives on innovation in combination therapies and non-antibiotic solutions.
- Strategic patents and generics shape a competitive yet accessible landscape.
- North America leads adoption, while Asia-Pacific emerges as a high-growth region.
“The issuance of this U.S. patent showcases the unique nature of our XYNGARI product candidate as a novel treatment for acne, if approved.” — Gerry Proehl, CEO of Dermata Therapeutics[9]
References
- https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
- https://atcddd.fhi.no/atc_ddd_index/?code=D10A
- https://www.cognitivemarketresearch.com/air-traffic-control--atc--simulator-market-report
- https://www.drugpatentwatch.com/p/generic-api/CLINDAMYCIN+PALMITATE+HYDROCHLORIDE
- https://www.verifiedmarketresearch.com/product/air-traffic-control-market/
- https://pharmacy.moh.gov.my/sites/default/files/document-upload/msom-2018-2022-15102024_0.pdf
- https://www.precedenceresearch.com/acne-medication-market
- https://go.drugbank.com/drugs/DB01190
- https://www.biospace.com/press-releases/dermata-expands-patent-portfolio-with-issuance-of-new-u-s-patent-for-next-generation-acne-treatment
- https://www.grandviewresearch.com/industry-analysis/acne-drugs-market
- https://www.ipcheckups.com/patent-landscape-analysis-how-to-5-steps/
- https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-106565
- https://patents.google.com/patent/US20170224743A1/en
- https://www.marketresearchintellect.com/product/global-anti-acne-drugs-market-size-and-forecast/
- https://www.pharmakb.com/drug-report/nadifloxacin
- https://www.fortunebusinessinsights.com/acne-treatment-market-103361
- https://www.towardshealthcare.com/insights/acne-treatment-market
More… ↓
